Furtado Cristiana Libardi Miranda, da Silva Santos Renan, Sales Sarah Leyenne Alves, Teixeira Louhana Pinheiro Rodrigues, Pessoa Claudia do Ó
University of Fortaleza, Experimental Biology Center, Fortaleza, Ceara, Brazil.
Drug Research and Development Center, Postgraduate Program in Translational Medicine, Federal University of Ceara, Fortaleza, Brazil.
Adv Exp Med Biol. 2023;1429:41-58. doi: 10.1007/978-3-031-33325-5_3.
Long non-coding RNAs (lncRNAs) are one of the most abundant and heterogeneous transcripts with key roles in chromatin remodeling and gene regulation at the transcriptional and post-transcriptional levels. Due to their role in cell growth and differentiation, lncRNAs have emerged as an important biomarker in cancer diagnosis, prognosis, and targeted treatment. Recent studies have focused on elucidating lncRNA function during malignant transformation, tumor progression and drug resistance. The advent of the CRISPR system has made it possible to precisely edit complex genomic loci such as lncRNAs. Thus, we summarized the advances in CRISPR-Cas approaches for functional studies of lncRNAs including gene knockout, knockdown, overexpression and RNA targeting in tumorigenesis and drug resistance. Additionally, we highlighted the perspectives and potential applications of CRISPR approaches to treat cancer, as an emerging and promising target therapy.
长链非编码RNA（lncRNAs）是最丰富且异质的转录本之一，在染色质重塑以及转录和转录后水平的基因调控中发挥关键作用。由于lncRNAs在细胞生长和分化中的作用，它们已成为癌症诊断、预后和靶向治疗中的重要生物标志物。最近的研究集中在阐明lncRNAs在恶性转化、肿瘤进展和耐药性过程中的功能。CRISPR系统的出现使得精确编辑诸如lncRNAs等复杂基因组位点成为可能。因此，我们总结了CRISPR-Cas方法在lncRNAs功能研究方面的进展，包括在肿瘤发生和耐药性中的基因敲除、敲低、过表达和RNA靶向。此外，我们强调了CRISPR方法作为一种新兴且有前景的靶向治疗手段在癌症治疗中的前景和潜在应用。
Zotero 插件